Autopsy report · NCT02314143
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
Cause of deathSlow enrollment
“The study was terminated early due to slow enrollment and limited numbers of viable tissue samples.”
Life of this trial
- Registered 2 months before it started.
- Ran for about 3 years 2 months before it stopped.
- 48 participants enrolled.
- Results were posted on the registry 2 years 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Industry
- Conditions
- Melanoma
- Interventions
- Dabrafenib; Trametinib
- Participants
- 48
- Sites
- 7
- Countries
- France, Spain
Trials that died the same way
- A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
“Due to low enrollment, this study was terminated early.” - MIRACLE EF Clinical Study
“The study was terminated early due to low enrollment.” - A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients
“This study was terminated early due to poor enrollment.” - A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
“This study terminated prematurely because of slow enrollment” - Evaluation of the Clinical and Economic Impact of painPRIMER in the Treatment of Low Back Pain in a Primary Care Setting
“The study was terminated on 02-Jun-2014 due to slow enrollment. The study was not terminated for reasons of either safety or efficacy.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.